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MOLECULARLY TARGETED NANOMEDICINE: ROLE OF HSP90 INHIBITOR AND
SOPHOROLIPIDS IN THE TREATMENT OF LUNG CANCER

An Abstract of the Thesis by
Shuguftha Naz

Lactonic sophorolipids (LSL) are a class of enzymatically modified glycolipids known to have HDAC
inhibition activity and anticancer properties. Ganetespib (GT), an Hsp90 inhibitor, is known for its
superior antitumor activity in several K-RAS mutant Non-Small-Cell Lung Cancer (NSCLC) cells.
In this study, a new anti-oxidant nanoplatform is formulated using the combination of these two
drugs, LSL and GT, in order to target both HDAC inhibition and Hsp90 signaling pathways in
NSCLC. Nanoceria (NC) is an excellent redox platform will be specifically used to supplement the
therapeutic potency of these drugs in the effective treatment of NSCLC. We hypothesized that the
therapeutic efficacy of GT will be synergistically accelerated by the HDAC inhibition and redox
activity of LSL and NC, respectively. For this, polyacrylic acid-coated nanoceria (NC-COOH) is
synthesized using solvent precipitation method and folic acid is conjugated using ‘click’ chemistry
in order to target NSCLC and to minimize adverse side effects. As a result of combination therapy,
enhanced ROS production is detected and more than 80% reduction in the cell viability is recorded
within 24 h of incubation. Migration assays indicated that the highly metastatic nature of NSCLC is
successfully restricted upon treatment of these drugs-loaded functional nanoceria. In addition,
various cell-based assays including detection of apoptosis and necrosis, HDAC inhibition, MTT and
fluorescence microscopy are performed to validate the highly effective combination therapy of
NSCLC. Together, our results represent for a unique combination of drugs and personalized
delivery system for the effective treatment of K-RAS driven undruggable NSCLC.
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CHAPTER I
Introduction
Histone acetylation and deacetylation plays a crucial role in the regulation of gene
expression.1 They are balanced by two most important enzymes histone
acetylases (HAT) and histone deacetylases (HDAC).2-4 Altered expression and
mutation of genes associated with HDAC are directly linked to cell proliferation and
tumor development.5,6 Studies have shown that HDAC inhibitors are known to alter
gene expression and influence on cellular growth arrest, cytotoxicity and induce
apoptosis.7-12 Thus, the development of HDAC inhibitors, their therapeutic role and
mechanism of action has received tremendous attention in the field of cancer
treatment.13,14 Lactonic sophorolipid (LSL) is a glycolipid molecule synthesized
from

specific

yeast

species.15,16

Many

reports

are

available

on

the

immunomodulatory and anti-inflammatory properties of LSL.17-20 However, studies
have reported on the anticancer activity of LSL on different cell lines including
pancreatic, esophageal and lung cancer.18-26 It is indicated that one of the
mechanisms for anti-tumor activity of LSL is the HDAC inhibition, where the histone
deacetylases are inhibited and interferes with the gene expression. 17
Lung carcinomas are currently the leading cause of cancer-related mortality
worldwide due to its poor prognosis, multidrug resistance (MDR) and low survival
rate.27-29 Approximately, more than 85% of lung cancer cases are related to non1

small-cell lung cancer (NSCLC) and the major histopathological subtypes are
adenocarcinomas, squamous cell carcinomas and large cell carcinomas. 28,30-34
Oncogenic K-RAS mutations in human NSCLC (10-30%) have gained resistance
to chemotherapy and radiation.35-37 Although K-RAS mutations are well known, yet
there is a lack of effective therapeutic options available for K-RAS driven NSCLC.35
Severe side effects, multidrug resistance and poor survival outcomes are the
limitations of current NSCLC therapies,38,39 and this is indicative of the urgency in
the development of an effective chemotherapy for the treatment of NSCLC.

Figure 1: Schematic representation of the mechanism of actions of the
combination of drugs: ganetespib and lactonic sophorolipid for the effective
treatment of NSCLC.
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Targeted delivery of two or more chemotherapeutic drugs specifically to tumor site
is becoming a popular choice for the effective treatment of cancer. The
combination therapy allows inhibition of separate tumorigenesis pathways that
overcomes severe side effects, multidrug resistance, and have potential to improve
treatment response. Considering the importance of combination therapy, a new
drug combination, ganetespib (GT) and LSL is proposed in this study. We
reasoned that GT is a second generation Hsp90 inhibitor, which leads to the
degradation of major client proteins. It disrupts important signaling cascades
responsible for cell proliferation and survival of tumor.40-43 GT is also known to have
potential antineoplastic activity and shown promising results in the treatment of
NSCLC in past few years.42,44-47 In addition, the use of nanotechnology-based drug
delivery system has become an emerging area of interest for better payloads,
biocompatibility and targeted delivery of chemotherapeutic drugs, which resulted
in minimal side effects.48-53 Recent studies indicated the huge potential of various
nanoparticles as drug carriers in cancer therapy, including targeted drug delivery,
diagnosis,

imaging,

and

treatment.31,54-57 Among

others,

cerium

oxide

nanoparticles (NC) has received considerable attention due to its excellent
catalytic and anti-oxidant properties on different cell systems.58-62 As an
antioxidant, many reports are available indicating its cytotoxic nature towards
cancer cells, whereas protective effects in certain neurodegenerative disorders. 63
Herein, we report an innovative combination therapy approach for the effective
treatment of NSCLC (A549 cells). Blend of chemotherapeutic drugs, LSL and GT,
are encapsulated into the folate-conjugated nanoceria, which minimizes the off-
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target effects of drug combinations. Additionally, the anti-oxidative nature of
nanoceria facilitates for the survival of healthy tissues, while in situ generation of
chronic oxidative stress in the tumor cells reduces its viability. This property of NC
supplements the synergistic therapeutic actions, where LSL plays an important
role in HDAC inhibition and GT inhibits the Hsp90 signaling pathways towards the
treatment of NSCLC (Figure 1).64,65 The therapeutic effects of this combination
therapy are examined by performing various cell-based assays including cell
viability, enhanced ROS, apoptosis and necrosis, migration and HDAC assays.
Taken together, findings from this study would provide clinically acceptable strong
support for the NSCLC treatment decision making and potential translational
applications of the nanomedicine.
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CHAPTER II
Results and Discussion
Synthesis and Characterizations of poly (acrylic acid) (PAA)-coated Cerium Oxide
Nanoparticles (PNC):
Previously reported water-based alkaline precipitation method was used to synthesize
polyacyrilic acid coated nanoceria (NC-COOH).66 The obtained yellow color solution of
nanoceria was centrifuged to get rid of agglomerates and bigger size particles and was
further purified by dialysis technique (MWCO 6-8 kDa) (1, Scheme 1).67 Optical lipophilic
DiI dye was encapsulated in NC-COOH (encapsulation efficiency, EEDiI = 85%) using
modified solvent diffusion method. DiI dye is important for optical imaging because of its
high extinction coefficient (ε > 125000 cm-1 M-1) and higher fluorescence emission (λmax
= 585 nm) and used as negative optical probe to evaluate the toxicity of carboxylated
nanoceria. To functionalize our nanoparticles, carboxylic acid groups of NC-COOH (2 X
10-3 mol) were conjugated with propargylamine (15 X 10-3 mol) using EDC (15 X 10-3 mol)
and NHS (15 X 10-3 mol) chemistry in the presence of MES buffer (pH = 6.0). In presence
of CuI catalyst, using click chemistry, folic acid was conjugated on the surface of
nanoparticles to target lung cancer expressing folate receptors on the surface (4 and 5,
Scheme 1). Click chemistry is the reaction between folate-azide (2 X 10-2 mol) and triple
bond of propargylamine (1.5 X 10-3 mol). The prepared folate nanoceria was further
purified using dialysis technique and then encapsulated with DiI dye via solvent diffusion
5

method, which is used as positive control for targeted delivery of drugs. Encapsulation of
therapeutic drugs, LSL and GT in folate nanoceria (5, Scheme 1, 1.0 X 10-3 mol, EELSL/GT
= 75%) using same modified solvent diffusion method was done for therapeutic
applications. Finally, these preparations were dialyzed for purification and stored at 4° C
for further characterizations.
Characterizations of PAA Polymer-Coated Functional Nanoceria.
The synthesized NC-COOH was characterized by FT-IR spectroscopy (Figure 2) to
confirm the presence of carboxyl groups on the surface as an indication of successful
coating of polyacyrilic acid. The presence of a carboxyl stretching band at 1685 cm -1
confirmed the presence of C = O stretching indicating the successful coating of PAA
polymer on nanoceria. PAA coating makes our nanoparticle sable, compatible and allows
efficient encapsulation of drugs. The carboxyl groups on the surface allow conjugation of
various functional groups for targeted delivery. Dynamic light scattering studies showed
the presence of monodisperse nanoceria preparation with an average hydrodynamic
diameter of 56.75 ± 2 nm (Figure 2B). The overall surface charge of the different
functional nanoceria preparations was assessed by ζ potential and was found to be -25.6
mV for NC-COOH and -11.8 mV for NC-FOL. (Figure 3A and 3B).
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Figure 2: The presence of PAA coating in NC was confirmed by the presence of acid
carbonyl band at 1685 cm-1 in FT-IR spectrum. Determination of the size of NPs using
dynamic light scattering (DLS) showing the average hydrodynamic diameter of 56.75 nm.
Conjugation of folic acid on the surface of nanoceria and successful encapsulation of
optical DiI dye in the polymer coating was confirmed by UV-Vis absorbance and
fluorescence spectroscopy using a high–throughput plate reader. The absorbance
spectrum of DiI encapsulating folate nanoceria (Figure 3E) confirmed the presence of
both DiI dye (λabs = 585 nm) and folic acid (λabs = 360 nm). This was further confirmed by
their corresponding fluorescence spectra (Fol: λem = 460 nm; DiI: λem = 600 nm, Figure
3D and 3F). The size and fluorescence of these nanoceria preparations were remained
to be unchanged for longer duration indicating the stable synthesis of nanoceria.
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Scheme 1: Schematic representation of redox cerium oxide nanoparticles. (1) Nanoceria
was synthesized using alkaline precipitation method with PAA coating on its surface. (3)
Propargylated NPs were synthesized using carbodiimide chemistry. Click chemistry has
been used to functionalize the NPs with folic acid (4 and 5). Co-encapsulation of dye and
chemotherapeutic drugs was done using solvent diffusion method (2, 4 and 5) to produce
desired functional NPs.
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Figure 3: Characterization of functional nanoceria. (A and B) Average zeta potential
(surface charge) of NC-COOH and NC-FOL was found to be -25.6 and -11.8 mV by DLS.
(C) UV-Visible absorption spectra at 360 nm and (D) Fluorescence emission spectra at
460 nm confirms the successful conjugation of folic acid on the surface of the NPs. (E)
Presence of folic acid and DiI dye is confirmed by the UV absorption bands at 360 nm
and 585 nm. (F) Fluorescence emission spectra of NPs encapsulated with DiI dye (λmax
= 600 nm).
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Drug release profiles:
To verify the drug release kinetics of our nanoparticle in the presence of appropriate
external environment, we determined the release profile of the drug and dye from the
nanocarrier at two different pH conditions (acidic – 6.0 and physiological – 7.4) in vitro.
According to hypothesis, the polymer coatings of nanoparticles are disrupted in acidic
environment thereby releasing the cargos. Time dependent study of released cargos was
determined using the plate reader.

Figure 4: Controlled drug release profiles of NC-LSL-FOL using dialysis method. (A)
Controlled release of LSL drug from encapsulated NPs with time in acidic pH (pH 6.0)
was observed and about 80% of drug is released within 6 h of time. However, minimal
release was seen at normal pH (pH 7.4). (B) Similarly, release of DiI dye in acidic pH was
studied at (λem = 585 nm) using UV where the absorption maxima increase with release
of time. However, there is no or minimal release of drug and dye at normal pH conditions.
In the cumulative release of drug at pH 6.0 as shown in Figure 4A, a burst release of
drug (80%) was observed within 6 h and then the release was stable. Whereas, the dye
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release was slower when compared to that of the drug. Maximum amount of dye was
released in 12 h of time (60%) and then remained stable (Figure 4B). In contrast, at
physiological pH, no detectable release of drug or dye was observed. These results
confirm that our nanoparticles release the cargos within the acidic environment of tumor
cells and are stable at normal pH.
Cell viability assay (MTT Assay):
In an attempt to assess the therapeutic efficacy of nanoceria loaded with cargos, a series
of cytotoxic experiments were conducted with different functional nanoparticles on two
different cell lines, A549 (folate-positive) and CHO (folate-negative) cells in a time
dependent manner. Briefly, cells (2500 cells/well) were seeded in 96-well plate and
incubated with various functional folate conjugated nanoceria preparations (35 µL, 1.0 X
10-3 mol) at 37°C followed by incubation of MTT. The data was collected at regular
intervals of time. Interestingly, upon incubation with LSL alone more than 40 % of cells
were found to be dead after 24 h of incubation. This was synergized by GT and both the
drugs in combination (NC-LSL-GT-FOL, 1.0 X 10-3 mol) showed more than 80% of cell
death within 24 h of incubation and when continued to 48 h, it showed 90% of cell death
(Figure 5A). However, nanoceria by itself without drugs showed minimal toxicity to both
the cancer cells and normal cells, indicating the biocompatibility of our redox-based drug
delivery system. No significant cytotoxicity was observed when CHO cells were incubated
with drug loaded folate nanoceria (Figure 5B) due to the absence of folate receptors. The
main characteristic of our nanoplatform is to minimize the side effects and increase the
uptake of drugs via active targeting by using folate conjugated nanoceria. From the
results, it is evident that LSL activity is accelerated by GT as result of synergistic effect.
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Thus, the targeted delivery of our functional nanoceria encapsulated with LSL and GT
would provide an excellent therapy for potentially addressing the MDR effect in the
treatment of undruggable NSCLC and other tumors.

Figure 5: Determination of cytotoxicity of formulated nanoceria using MTT assay. (A)
More than 80% of cells were dead within 24 h when incubated combinational drugs
carrying nanoceria, whereas only 40% toxicity was observed with delivery of single drug.
(B) On the other hand, minimal toxicity was observed when functional nanoceria was
incubated with CHO cells (FR -), suggesting targeted delivery of drugs specifically to
tumor site.
Confocal Laser-Scanning Microscopy:
To shed light on dye release monitoring in living cells, we recorded a set of laser scanning
fluorescent microscopic images to visualize the intracellular dye and drug release. During
the imaging process, to avoid heat effect-induced cell death the exposure time of laser
was given shorter than 400 ms. We hypothesized that folate conjugated nanoceria would
target tumors overexpressing folate receptors and gets internalized, minimizing the
toxicity to healthy cells. When carboxylated nanoceria encapsulated with combinational
12

drugs (NC-LSL-GT-COOH, 1.0 X 10-3 mol, Figure 6A-6D) was incubated in A549 cells,
there was no or minimal internalization. This is due to the lack of folate ligands on the
surface of our nanoparticle which could not target folate receptors. According to our
hypothesis, folate conjugated nanoceria will gets internalized in the folate expressing
tumors. To validate this, A549 cells were incubated with folate nanoceria encapsulated
with DiI dye and interestingly, internalization of nanoceria with the release of dye was
observed as the cytoplasm was found to be red (Figure 6E-6H). To further demonstrate
the folate receptor-mediated internalizations, A549 cells were incubated with LSL and GT
loaded folate nanoceria (1.0 X 10-3 mol) huge change in cellular morphology was
observed where the cytoplasm is ruptured and the nucleus is disorganized (Figure 6I6L). These results signify the local targeting and delivery of drugs effectively to cancer
cells. When CHO cells were incubated with drugs encapsulating folate nanoceria, there
was no or minimal internalization due to the lack of folate receptors on the surface of CHO
cells (Healthy cells). This confirms the tumor-targeting ability of our functional nanoceria,
while minimizing the toxicity to healthy cells. (Figure 6M-6P). Taken together, these
results indicate the possibility of our designed nanoplatform to be used for targeted
delivery in clinical trials.
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Figure 6: Representative fluorescence microscopic images of the in vitro cellular imaging
and drug delivery experiments. No or minimal internalization of carboxylated NPs loaded
with combination of drugs was observed in A549 cells due to absence of folic acid on
surface of NPs (A-D). Effective internalization of folate NPs with no drugs was observed
due to folate receptor-mediated endocytosis (E-F). However, when drugs-loaded folate
nanoceria was incubated with A549 cells, substantial amount of cell death was observed
(I-L). In contrast, minimal internalization of folate NPs was observed in CHO cells due to
the absence of folate receptors on the surface of the CHO cells (M-P), indicating the
targeted drug delivery. Nucleus stained with DAPI dye (blue).
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Cytosolic ROS detection assay:
A newer approach to achieve better anticancer therapy is to enhance ROS levels
selectively in the cancer cells. The generation of ROS in the cell is determined by
Dihydroethidium (DHE), a fluorescent dye which is oxidized to 2-hydroxyethidium in the
presence of reactive oxygen species and gives red fluorescence after intercalating within
the nuclei. Previous studies have shown ROS generation via HDAC inhibition as one of
the mechanisms by which LSL exerts its antitumor activity. To determine the GT
synergizes the ROS production of LSL, A549 cells were treated with combinational drugs,
LSL and GT carrying folate nanoceria (5, 1.0 X 10-3 mol, Scheme 1). Briefly, A549 cells
were seeded into 12-well plates (10000 cells/well) and when confluent, they are incubated
with different functional nanocarriers: (1) folate nanoceria without drug (NC-FOL), (2)
folate nanoceria with GT alone (NC-GT-FOL), (3) folate nanoceria with only LSL (NCLSL-FOL), (4) folate nanoceria with combinational drugs (NC-LSL-GT-FOL). After 6 h of
treatment of drugs, the cells were washed and stained with cytosolic cell permeable probe
dihydroethidium (DHE) for 30 min. As expected, the cells treated with folate nanoceria
showed minimal fluorescence due to limited ROS stress (Figure 7A-i). Folate nanoceria
with GT showed significant amount of fluorescence indicating the stress induced by ROS
(Figure 7C-iii). In contrast, folate nanoceria encapsulated with only LSL showed elevated
ROS levels as observed by higher fluorescence intensity (Figure 7B-ii). This is due to
the cytotoxicity of LSL via HDAC inhibition pathway. When incubated with combinational
drugs (NC-LSL-GT-FOL, 1.0 X 10-3 mol, 5, Scheme 1), there was huge rise in the levels
of ROS Figure 7D-iv and this validates that the synergistic effect of GT improves
therapeutic efficacy of LSL by trigerring ROS generation.
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Figure 7: Determination of ROS generation. Incubation of A549 cells with different
nanocarriers shows the increase in fluorescence due to increased ROS levels. Due to the
effect of synergism, ROS levels are increased in order of folate nanoceria to folate
nanoceria with combinational drugs.
In addition, quantification of ROS was determined by calculating the numerical data of
fluorescence intensities from each fluorescence microscopic images using commercial
ImageJ software and the graph was plotted as shown in Figure 8.
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Figure 8: Quantification of ROS: Amount of ROS generation was quantified directly from
the microscopic images using Image J software. Results showed relatively higher
fluorescence from A549 cells treated with combinational drugs due to the presence of
increased amount of ROS.
Apoptosis and necrosis detection assay:
Increased ROS production is incriminated in apoptosis and has been reported as an early
event which is followed by necrosis. Having known that our functional nanoceria produces
ROS, next we want to further elucidate the correlation between ROS generation and
apoptosis induction. In these experiments, A549 cells were exposed to various
nanocarriers, NC-FOL, NC-GT-FOL, NC-LSL-FOL and NC-LSL-GT-FOL (1.0 X 10-3 mol)
for 24 h. In our study, the apoptotic and necrotic cells were distinguished on the basis of
their cell integrity and morphology by using fluorescence microscope. Upon staining with
Annexin V-FITC and Ethidium homodimer III, the apoptotic and necrotic cells exhibited
green and red fluorescence respectively. This is due to the various morphological and
biochemical changes occurring the tumor cells including the translocation of
17

phosphatidylserine (PS) due to apoptosis. As demonstrated in the Figure 9A, folate
nanoceria shows fewer apoptotic cells which is related to the antioxidant nature of
nanoceria. Annexin V and ethidium homodimer staining pattern determines that NC-LSLFOL leads to early and late apoptosis (major green spots for apoptotic cells and fewer
red spots for necrotic cells, (Figure 9C). Upon treatment with combinational drugs,
increased apoptotic and necrotic cells were seen (Figure 9D) thus confirming that
treatment of GT accelerates the LSL apoptosis induction leading to extensive loss in
membrane integrity, eventually leading to cell death via necrosis. Taken together, our
results suggest that combination of LSL and GT might provide better anti-tumor effect
through synergistic effect in the treatment of NSCLC. In addition, the development of
functional nanoceria encapsulated with combinational drugs would be an ideal drug
delivery system for targeted combination therapy of NSCLC and other tumors.
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Figure 9: Detection of apoptotic and necrotic cell death by fluorescence microcopy using
annexin V-FITC and ethidium homodimer III. (A) Healthy cells emitted limited
fluorescence representing early apoptosis. (B & C) When incubated with single drugs,
green fluorescence was emitted by apoptotic cells (D) Combinational drugs exhibited both
green and red fluorescence due to late apoptotic and necrotic cells. (a, b, c and d)
represents corresponding bright field images.
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Migration assay:
Metastasis is the deadliest aspect of cancer and remains the principal cause of death
despite of research aimed at restricting tumor growth. One such case is with K-RAS driven
NSCLC. To assess whether our combinational drugs carrying nanoceria is capable of
inhibiting the migration of tumor cells; we performed transwell migration assays. Briefly,
in these experiments, A549 cells were serum starved and treated with functional
nanoparticles (1.0 X 10-3 mol) and incubated for 24 h by seeding in upper invasion
chamber. When incubated with only nanoceria (no drugs, NC-FOL) our results showed
that the cells migrated from invasion chamber to the lower feeder tray containing 10%
FBS (CTRL, Figure 10). However, upon incubation with combinational drugs, the
migration ability of cells has decreased considerably as noticed by the change in
fluorescence intensity (Figure 10). Collectively, our results demonstrated that the
combinational drug therapy of LSL and GT along with the functional nanoceria might play
an important role in preventing the metastatic nature of NSCLC.
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Figure 10: Determination of anti-migratory effect of highly metastatic lung cancer cells
via migration assay. As represented, control (no drugs, red lines) showed significant
migration of cells. Whereas, nanoceria with combinational drug (black lines) had showed
minimal migration as the drugs are capable of inhibiting the metastatic nature of the cells.
HDAC Inhibition assay:
For the detection of HDAC inhibition activity of lactonic sophorolipids, we performed the
fluorescent HDAC inhibition assay according to manufacturer protocol. As presented
(Figure 11), positive control (HeLa extract, has HDAC activity) has shown high
fluorescence intensity as the substrate containing acetylated lysine residue is
deacetylated by the HDAC enzyme. In contrast, negative control, Trichostatin had shown
minimum fluorescence as the HDAC is completely inhibited and therefore the acetylated
residue is not deacetylated. When incubated with our functional nanoparticles (NCLSL/GT-FOL and NC-LSL-FOL), significant fluorescence was seen as the acetylated
HDAC substrate is not deacetylated due to the HDAC inhibition. As a result, there is a
reduction in fluorophore intensity in the sample wells (low fluorescence intensity), when
21

compared to positive control thereby confirming that lactonic sophorolipids follows the
HDAC inhibition pathway leading to the apoptosis. However, ganetespib, the
combinational drug of LSL in our study is showing a modest synergistic effect during this
mechanism.

Figure 11: Assessment of inhibition of histone deacetylase (HDAC) by lactonic
sophorolipids (LSL) in comparison with positive and negative controls. As depicted,
positive control shows enormous inhibition and the drugs had significant effect on HDAC
inhibition with that of negative control.
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CHAPTER III

Experimental Methods
Materials:
Cerium nitrate hexahydrate (Ce(NO3)3), Polyacrylic acid (PAA), Ammonium hydroxide
(NH4OH), Folic acid, N-hydroxysuccinimide (NHS), 2(N—morpholino) ethanesulfonic acid
(MES) sodium salt, Tetrahydron furan, acetonitrile, Sodium azide, Ethanol, Isopropanol
and Propargylamine (PA) were purchased from Acros organics and used without further
purification. Near infrared dye (DiI-D282) was obtained from Life technologies. N, N’dimethyl formamide (DMF) and Dihydroethidium (DHE) dye was purchased from Science
lab and Cayman chemicals respectively. N, N’-dimethyl sulfoxide (DMSO), 3-(4, 5dimethylthiazol-2-yl) - 2, 5-diphenyltetrazolium bromide (MTT) and (1-ethyl-3-[3(dimethylamino) propyl] carbodiimide hydrochloride) (EDC) were obtained from Sigma
Aldrich and used as received. 4, 6-diamidino-2-phenylindole (DAPI-D1306) was
purchased from Invitrogen. Dialysis membrane were received from spectrum
laboratories. Paraformaldehyde and H2O2 were received from electron microscopy
sciences. Fetal bovine serum (FBS) and 5X Annexin binding buffer were purchased from
BD biosciences, whereas Gantespib, Isopropyl alcohol, Apoptosis and Necrosis
quantification kit (FITC-Annexin V, Ethidium homodimer III) were obtained from Biotium.
Migration assay kit and HDAC inhibition fluorometric assay kit was obtained from Millipore
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and Biovision respectively. The human lung carcinoma cell line A549 cells (NSCLC) and
Chinese hamster cells (CHO) were obtained from ATCC (U.S.A). Dulbecco’s modified
eagle (DMEM) medium and Kaighn’s modification of Ham’s F12K cell culture medium
were purchased from Corning.
Synthesis of Poly (acrylic acid)-Coated Nanoceria (NC-COOH) (1):
To synthesize PAA coated nanoceria, previously reported alkaline-based precipitation
method was followed, where the cerium oxide nanoparticles were precipitated from a
solution of ammonium hydroxide containing cerium salt and PAA. The synthetic
procedure involves the preparation of two different solutions – Solution A: cerium nitrate
(0.9 g) in 2.5 ml of DI water, Solution B: PAA (0.9 g) in 10 ml of DI water. 30 ml of
ammonium hydroxide was taken in a beaker and was stirred at room temperature and
solution A was added to it followed by addition of solution B. We can notice the color
change from colorless to brown within 5 min of stirring and became deep yellow after 24
h, indicating the preparation of stable nanoceria. The reaction mixture was centrifuged
thrice at 3000, 3500 and 4000 rpm for 15, 20 and 20 min respectively to obtain smaller
size nanoparticles. The solution was further purified by dialysis technique using a dialysis
bag of molecular weight (MWCO) 6-8K against DI water and finally with phosphate buffer
saline (PBS, pH = 7.4) to remove ammonium hydroxide by selective and passive diffusion
through a semi-permeable membrane (dialysis tubing) (Scheme 1). The purified
nanoceria was stored at 4°C for further characterizations. Successful coating of PAA on
nanoceria was characterized by Fourier Transform Infra-Red (FT-IR) spectroscopy.
Overall size and surface charge were measured using dynamic light scattering (DLS)
technique.
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Synthesis of propargylated or alkynated NC (3); Carbodiimide chemistry:
Propargylated NC was synthesized by adding freshly prepared EDC (15 X 10-3 mol)
solution followed by addition of NHS (15 X 10-3 mol) in 200 µL of MES buffer (0.1 M), pH
= 6.0, after brief mixing. The reaction mixture was incubated for an additional 3 min at
room temperature and then propargylamine (15 X 10-3 mol) dissolved in DMSO was
added dropwise and mixed. The reaction was continued for 4-6 h for completion at room
temperature. The resultant propargylated NC was purified against PBS (pH = 7.4) using
the dialysis method to remove the unreacted reagents from the solution.
Synthesis of Aminopropyl azide:
Aminopropylazide was synthesized by reacting chloropropyl amine (7.0 g, 75.26 mmol)
and sodium azide (14.23 g, 225.81 mmol) in 40 mL of distilled water. The reaction was
carried out at 800 C for 20 h. The reaction mixture is then concentrated using rotary
evaporator at high vacuum. 2 g of KOH was added and the product was extracted using
diethyl ether. Subsequently, the reaction mixture was dried over anhydrous sodium
sulfate and concentrated. Purification of the product was done by column chromatography
using 4% ethyl acetate in petroleum ether.
Synthesis of folate-azide; Carbodiimide chemistry:
To the solution of folic acid (0.05 g, 0.12 mmol) in 7 mL phosphate buffer saline (PBS, pH
7.4), freshly prepared EDC (0.021 g, 0.11 mmol) followed by NHS (0.013 g, 0.11mmol) in
0.25 mL MES buffer (pH = 5.0) were added and then incubated at room temperature for
about 3. To this resulting mixture, add dropwise aminopropyl azide (0.0014 g, 0.11 mmol)
in 0.5 mL of MES (pH = 5.0) and incubate it for 3 h at room temperature. The carboxyl
groups of folic acid react with azide and forms azide-functionalized folic acid.
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Synthesis of folate conjugated NC (NC-FOL) (4 and 5) using “click chemistry”:
To the solution of alkynated NC suspension (2 mL, 1.5 X 10-3 mmol) in bicarbonate buffer
(pH 7.4) and folate-azide (FoL ̴ N3, 2 X 10-2 mol), catalytic amount of CuI catalyst (1 X
10-3 mmol) in DMF was added and incubated on table mixer for overnight at room
temperature. The resulting folate conjugated NC was purified by dialysis to remove
unreacted materials. The purified product was stored at 4°C for further characterizations.
Encapsulation of DiI dye (2 and 4): Modified solvent diffusion method:
For dye encapsulation, solvent diffusion method has been used. To 1 mL of nanoceria
(NC-COOH or NC-FOL) suspension, near infrared DiI dye (1 µL of 1 µM DiI dye in 100
µL of DMSO) was added dropwise with continuous stirring at 1500 rpm at room
temperature. The solution was incubated on table-mixer for 3 h and was dialyzed against
PBS (pH = 7.4) for 2 h to remove free dye from the solution. Successful encapsulation of
DiI was further confirmed using UV-Vis and fluorescence spectrophotometric analyses.
The purified dye-labeled nanoceria was stored at 4°C for further studies.
Coencapsulation of Lactonic sophorolipids (LSL), Ganetespib (GT):
Using a similar solvent diffusion method, drug or combination of drugs and dye were coencapsulated. Briefly, a solution of either LSL and DiI or LSL-GT-DiI or GT and DiI (2 µM
of the drug in 100 µL DMSO) was added dropwise to 2 mL of vortexing NC-FOL
suspension, followed by overnight incubation. The drug-encapsulating functional NC-FOL
were dialyzed against PBS (pH = 7.4) for 3 h. The purified suspension was stored at 4°C
for further characterizations. The presence of DiI dye was confirmed by using US-Vis and
fluorescence spectrophotometry.
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Characterizations of Functional Nanoceria:
Fourier transform infrared spectroscopy (FTIR):
To verify the surface functionalities of our synthesized nanoceria, we performed FTIR
studies using Perkin-Elmer’s Spectrum. PAA coated nanoceria was air dried and the
powdered crystals were collected. FT-IR spectra of dried PAA coated nanoceria and PAA
polymer was recorded and compared to confirm the successful coating of PAA on the
synthesized nanoparticles.
Dynamic light scattering (DLS):
The average size distribution and surface charge of the functional nanoceria were
obtained using dynamic light scattering technique. Malvern’s nano-ZS90 zeta sizer was
used for DLS studies.1 ml of NC-COOH was taken in the cuvette and measured for size
using standard procedure set in Malvern Zetasizer. For measuring zeta potential, the
sample was diluted with DI water and is carefully loaded in electrode without air bubble
and the zeta potential is measured and recorded.
Spectrophotometric analysis:
UV-vis and fluorescence spectroscopic studies of functional nanoceria were recorded
using TECAN’s infinite M200 PRO high throughput plate reader to confirm the successful
conjugation of folic acid ligands on the surface of nanoceria for targeted drug delivery.
Similarly, the studies were also performed for the presence of DiI dye in the nanoparticles
for optical imaging. The procedure involves the addition of 75 µL of suspension in Thermo
Fisher 96 well plate and measuring the absorbance and fluorescence at 300-800 nm and
585 nm wavelengths respectively.
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In vitro cell studies:
Cell Culture:
Human lung cancer cells (A549 cells) and Chinese Hamster ovarian cells (CHO cells –
normal cells) were obtained from ATCC. A549 cells were maintained in a 10% FBScontaining DMEM medium supplemented with 1% antibiotic, whereas, CHO cells were
propagated in 10% FBS containing Ham’s F12K media containing 1% penicillinstreptomycin antibiotic. Cells were grown under 5% CO2 atmosphere at 37° C in a
humidified incubator.
Cell viability assay (MTT Assay):
To determine the time-dependent cytotoxicity, two different cell lines, lung carcinoma
(A549 cells) and Chinese hamster ovarian cells (CHO cells) were used. Cells were
seeded in 96-well plates at a density of 3500 cells per well and treated with various
functional folate conjugated nanoceria (1.0 X 10-3 mol) and incubated at 37° C for different
time points. Each well was washed twice with PBS and then incubated with 30 µL of 5mM
MTT solution. After 4-6 h of incubation, the resulting formazan crystals (purple color) were
dissolved in acidic isopropanol (75 µL) and the absorbance was recorded at 570 nm using
TECAN’s microplate reader. The assay was carried out in triplicates and the results are
reported.
Drug release profiles:
The in vitro dye/drug release studies were carried out by using a dynamic dialysis
technique at 37° C. Drug/dye-loaded nanoparticles were packed in a dialysis bag and
suspended in 2 different environments of PBS (200 mL, pH 7.4 and 6). The amount of
drug/dye molecules released from the nanoparticles into the PBS solution was
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determined at regular intervals of time by taking 1 mL aliquots from the PBS solution and
replacing the same with PBS solution. Fluorescence emission was measured at 585 nm
for DiI dye. The concentration of dye released was calculated using standard calibration
curve and the cumulative release versus time was calculated using the following equation:
Cumulative release (%) = (dye released)t / (dye released)total X 100
Where, (dye released)t is the amount of dye released at time t, and (dye
released)total is the total dye present in the dye/drug encapsulated nanoparticles.
Confocal Laser-Scanning Microscopy:
Lung carcinoma cells (A549 cells) and Chinese Hamster Ovarian cells (CHO – Normal
cells) were seeded into the culture dishes and grown overnight. Once the cells are 75%
confluent, different functional drug loaded nanoparticles (NC-COOH, NC-DiI-FOL, NCLSL-GT-DiI-FOL, 1.0 X 10-3 mol) were treated to the cells and incubated at 37° C for 24
h. The cells were washed thrice with 1X PBS (pH = 7.4) and were fixed with 4%
formaldehyde solution for 15 min at room temperature. The cells were again washed with
1X PBS before treating with DAPI dye (5mg/mL) for staining cell nuclei. The cells were
then washed with 1X PBS and optical images were taken using fluorescence microscope
(Olympus IX73) for cellular internalization of dyes and killing of cells. For the control
experiment, CHO cells were treated with NC-LSL-GT-DiI-FOL (1.0 X 10-3 mol) and the
results were shown.
Cytosolic ROS detection assay:
To know the mechanism of the killing process of cancerous cells, various assays were
performed, of which, ROS is one among them. This assay determines the process of
induction of stress to the cells by the generation of reactive oxygen species. A549 cells
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were seeded in 12-well plates at a density of 10000 cells per well and treated with
nanoparticles encapsulated with different drugs (1.0 X 10-3 mol) and incubated at 37° C.
After 6 h of incubation, the cells were washed thrice with 1X PBS and stained with 20 µL
of DHE fluorescent probe for about 30min at room temperature followed by washing the
cells twice with 1X PBS. Subsequently, the cells were fixed with 1 mL of
paraformaldehyde solution. After fixation, the cells were washed with 1X PBS, stored with
2 mL PBS in each well and optical images were taken using fluorescence microscope.
Quantification of ROS fluorescent images:
Using ROS fluorescent images, the amount of ROS was quantified using commercial
ImageJ software. Particular cell from each treated well was selected to get a stack of
values for the area, integrated density, and mean fluorescence of background readings.
The corrected total cell fluorescence (CTCF) for each well was calculated using the
formula:
CTCF = integrated density – (area of selected cell X mean fluorescence of
background readings).
Apoptosis and necrosis detection assay:
For the assessment of apoptosis and necrosis, Annexin V-FITC and Ethidium homodimer
III was used. This assay is based on the translocation of phosphatidylserine (PS) from
the plasma membrane to the cell surface soon after the initiation of apoptosis. The
translocated PS can be easily detected by a protein, Annexin V in conjugation with FITC
which has the strong affinity for PS. Briefly, A549 cells were seeded in 12-well plates at
a density of 10000 cells per well. After confluence, cells were treated with different
preparations (NC-FOL, NC-LSL-FOL, NC-GT-FOL and NC-LSL-GT-FOL, 1.0 X 10-3 mol).
30

After 6 h of incubation, the cells were washed twice with 1X PBS and stained with two
different dyes, 5 µL of FITC-annexin buffer and 5 µL of ethidium homodimer III and
incubated for 15 min in the dark. Later the cells were washed twice with 1X binding buffer
and fixed with 4% formaldehyde solution and the cells were covered with 1X binding
buffer. Multiple fluorescence images were taken using two filters: green fluorescence
represents apoptosis; red fluorescence indicates necrosis.
Migration Assay:
Cell migration is a multi-step process that plays an important role in the progression of
cancer and other diseases. It is the movement of cells from one area to another in
response to a chemical signal. Currently, determining the migratory and invasive capacity
of tumor cells and elucidating their mechanisms is more important for cancer diagnosis
and treatment. Herein Chemicon QCM 96-well cell migration assay kit from Millipore was
used to evaluate the migration of cells in presence of functional nanoparticles in vitro.
Experimental procedure involves the incubation of serum starved A549 cells for 24 h.
Next, the cells were harvested and treated with the functional nanoparticles (NC-LSL/GTFOL). Subsequently, the cells were seeded in invasion chamber of the migratory assay
kit coated with collagen layer. The feeder tray contained 10% FBS media and the
complete set up was incubated at 37° C for 24 h to allow the migration of cells. Later, the
migratory cells were dislodged completely from the invasion chamber and placed on new
feeder tray containing cell detachment buffer and incubated for 30 min. Finally, a diluted
solution of CyQuant GR dye and cell lysis buffer was added to stain migratory cells and
the fluorescence intensity was measured at an emission wavelength of 480/520 nm.
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HDAC Inhibition Assay:
Acetylation and deacetylation of histone proteins influence the gene expression by
modulating the chromatin structure. Two enzymes, histone acetyltransferase (HAT) and
histone deacetylase (HDAC) mediate the balance between acetylated and deacetylated
states. HDAC has a wide spectrum of cellular functions including regulation of gene
transcription, translocation of transcriptional factors and apoptosis by altering acetylation
of various proteins. Several studies have shown that inhibiting HDAC in cancer cells leads
to cell differentiation and reduced cell growth, making HDAC notable and attractive
antitumor target for cancer therapy.
HDAC fluorometric assay kit from Biovision was used to determine the HDAC inhibition
ability of lactonic sophorolipids (LSL). The assay was performed according to
manufacturer’s protocol. HeLa nuclear extract and Trichostatin A were used as positive
and negative controls respectively. Briefly, A549 cells were seeded in 96-well microtiter
plates (10000 cells/well) and after 80% confluence, the cells were treated with
nanoparticles (NC-LSL/GT-FOL and NC-LSL-FOL) and incubated at 37° C for 24 h.
Positive and negative controls were added along with HDAC assay buffer and the reaction
was initiated by adding HDAC fluorometric substrate and incubating for 30 min or longer
as desired by the drugs. Later, the HDAC lysine developer was added to stop the reaction
and is incubated for additional 15 min. The plate is then read for fluorescence intensity at
380/460 nm.
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CHAPTER IV
Conclusions
In conclusion, we have successfully synthesized functional nanoceria with
combinational drugs as a drug vehicle for the treatment of K-RAS driven NSCLC.
Targeted delivery is achieved through folate conjugation of nanoceria and the
synergistic effect of combinational drugs was observed. Encapsulation studies and
enhanced stability confirmed excellent drug payload with high therapeutic efficacy
and reduced toxicity. More than 90% of cells were dead when incubated with
combinational drugs as reflected by combinational therapy. Results indicated that
GT synergizes the activity of LSL, as confirmed by MTT and ROS assays.
Apoptosis and necrosis assays further proved the synergistic effect of drugs by
increased apoptotic and necrotic cells. In addition, migration assay validated the
important role of combinational drugs in preventing lung cancer metastasis.
Therefore, our study of delivering combinational drugs using functional nanoceria
provides clinically actionable information that could impact treatment decisions for
individuals with K-RAS driven NSCLC.
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